Inanovate was founded in Massachusetts by two Babson MBA graduates, after winning first prize at the Babson Business Plan competition. The company has since grown operations in Massachusetts, North Carolina and the UK, forming close alliances with leading commercial and academic institutions. Inanovate has combined expertise from nano-scale physics, bio-engineering, bio-chemistry and biotechnology to create a unique mutliplexed protein screening technology called Longitudinal Assay Screening (LAS), designed to help advance the development and implementation of next generation therapeutics and clinical diagnostics. Inanovate has recently completed testing and demonstration of the world's first protein detection and measurement platform to integrate LAS - The Bio-ID 400.